Method of treatment of liver metastases. RU patent 2474423.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely oncology, and may be used for treating liver metastases. That is ensured by introducing the hydrophobic suspension Teraftal® containing a radiopaque substance into a hepatic artery. The introduction is aided by X-ray. It is followed by the introduction of ascorbic acid started one day after the arterial embolisation and continued for seven days daily. A single dose of ascorbic acid makes 100 mg.

EFFECT: invention provides partial metastasis regression in limited hepatic metastatic involvement that leads to prolonging average-expectancy life.

2 dwg, 2 ex

IPC classes for russian patent Method of treatment of liver metastases. RU patent 2474423. (RU 2474423):

A61P35 - Antineoplastic agents

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K31/40 - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61K31/375 -

Another patents in same IPC classes:

Method for prevention of complications in treating patients with lung cancer / 2474421
Invention refers to medicine, namely oncology and radiology, and concerns prevention of complications in treating the patients with lung cancer. For this purpose, a complex of radiation and antioxidant therapy involves antioxidant preparations containing derinat - conducting radiation therapy, antioxidant and drug-induced therapy differing by the fact that the antioxidant drug-induced therapy involves the prescribed per os derinat-containing preparations - Coletex-gel-DNA and Coletex-gel-DNA-D. The antioxidants are administered in the following regimen: for 10-15 days before the beginning of the radiation therapy Coletex-gel-DNA 15-20 g 1-3 times a day; during the entire course of the radiation therapy, Coletex-gel-DNA-L 25-30 g 15 minutes before a session; after the termination of the radiation therapy for 10-15 days Coletex-gel-DNA-L 25-30 g before and after each meal.

Method of treating oesophageal cancer / 2474420
Invention refers to medicine, namely oncology and concerns treating oesophageal cancer. That is ensured by the intravenous introduction of 5-fluoruracil twice a week, 300 mg/m in one introduction every 2-3 days in a combination with the oral introduction of Coletex-gel-DNA-L 10-15 ml 3 times a day. On the other days of week, the hydrogel material Hydrogel Tissue Coletex-5-ftur is introduced in a dose 5 ml once a day; 10-15 min before the introduction of the gel material, Coletex-gel-DNA-L 10-15 ml is additionally introduced. Length of the therapeutic course is 4 weeks.

Human protein tyrosine phosphatase beta binding antibodies (hptpβ), and use thereof / 2473565
Invention refers to medicine. What is presented is an antibody produced of hybridoma ATCC No. PTA-7580 specific to human protein tyrosine phosphatase beta (HPTPβ). What is described is a Fab version of said antibody, as well as versions of method of treating and pharmaceutical compositions based on the use of the antibodies. Binding the antibody and HPTPβ intensifies Tie-2 signal transmission, and thereby increases angiogenesis, whereas binding the Fab antigen-binding antibody fragment and HPTPβ inhibits Tie-2 signal transmission, and thereby reduces angiogenesis.

Conjugates of disorazol, based pharmaceutical compositions, said conjugates for preparing drug, kit and method for preparing them / 2473562
Present invention refers to conjugates of Disorazol with cell adhesion molecules, such as peptides, proteins, hormones, blood proteins, and methods for preparing conjugates.

Combined chemotherapy and immunotherapy / 2473560
Invention refers to biotechnology and medicine, more specifically to the use of EGFRvIII in a combination with temozolomide, and may be used for treating a tumour in an individual. A method of treating the tumour in the individual provides introducing into the individual an amount of temozolomide effectively inducing lymphopenia; monitoring of white blood cell count after introducing temozolomide; and introducing into the individual an effective amount of the EGFRvIII peptide for white blood cell count recovery in a point of the least white blood cell count. Introducing the EGFRvIII peptide into the individual may be combined with introducing the effective amount of GM-CSF as an adjuvant.

Therapeutic agent on pyrroline derivates for prevention of tumorous cell death, method for preparing it and method for using it / 2473551
Invention refers to compound presented by Formula

16-(1,2,4-oxadiazol-3-yl)-15,16-epoxilabdanoids possessing cytotoxic activity on human tumour cells / 2473550
Invention refers to organic chemistry, specifically to 16-(1,2,4-oxadiazol-3-yl)-15,16-epoxilabdanoids of formula

Pyrimidine compounds, compositions and methods of use / 2473549
Invention refers to new pyrimidine derivatives and their pharmaceutically acceptable salts possessing the properties of a mTOR kinase inhibitor. In formula (I): A represents a 6-8-member mono- or bicyclic heterocyclic ring containing 1 to 2 heteroatoms optionally specified in N and O as apexes of the ring and having 0-2 double bonds; and wherein the ring A is additionally substituted by 0 to 2 substitutes RA specified in a group consisting of -ORa, -Rc and -(CH2)1-4-ORa wherein Ra is optionally specified in hydrogen and C1-6alkyl; Rc represents C1-6alkyl; G is specified in a group consisting of -C(O)-, -OC(O)-, -NHC(O)- and -S(O)0-2-; B is specified in a group consisting of phenylene and 5-6-member heteroarylene consisting 1-2 nitrogen heteroatom as apexes of the ring, and substituted by 0 to 1 substitutes RB specified in F, Cl, Br, I and Rp; wherein Rp represents C1-6 alkyl; D is specified in a group consisting of -NR3C(O)NR4R5, -NR4R5, C(O)NR4R5, -NR3C(=N-CN)NR4R5, -NR3C(O)R4, -NR3C(O)OR4 and -NR3S(O)2R4, and wherein the group D and a substitute placed on an adjoining atom in the ring B, optionally combined to form a 5-6-member heterocyclic or heteroaryl ring containing 1 to 3 heteroatoms specified in N, O and S, as apexes of the ring and substituted by the substitute 0-1 RD. The R1-R5 radical values are presented in the patent claim.

Heterocyclic nitrogen pyrrole derivatives, producing them and pharmaceutical application / 2473543
Invention refers to new pyrrole nitrogen-containing heterocyclic derivatives of formula (I) or their pharmaceutically acceptable salts:

Therapeutic preparation of male larval bees having immunomodulatory action / 2473355
Invention refers to pharmaceutical industry, namely a therapeutic preparation of male larval bees having immunomodulatory action. The therapeutic preparation of male larval bees having immunomodulatory action possessing a yellow powder prepared by grinding male larval bees to a homogenous biomass added with an aqueous-alcohol propolis extract and fine pollen; it is followed by freezing the paste and sublimation drying in a vacuum chamber in the certain environment.

Composition possessing adaptogenic, hepatoprotective and immunomodulatory action / 2473358
Invention refers to pharmaceutical industry and concerns an ergogenic formulation possessing adaptogenic, hepatoprotective and immunomodulatory action, and may be used in hepatic diseases, in decreases in immunity and increase in performance efficiency and tolerance. The composition contains burnut extract, zinc aspartate, magnesium aspartate, vitamin B6, water in certain proportions of the ingredients.

Method of treating drug-induced liver injury in children suffering from tuberculosis / 2473346
Declared invention refers to medicine. The anti-tuberculosis preparations are cancelled, while Ursosal 20 mg/kg is single administered per os, and Enterosgel 10-15 g for 3 days. Then, a dose of Ursosan is reduced to 12-15 mg/kg a day with underlying reinitiation of the anti-tuberculosis preparations, and the Ursosan therapy is continued until the ALT value appears to be below an upper limit of normal.

Method of treating non-alcoholic fatty liver disease / 2473342
Invention relates to medicine, namely to gastroenterology and can be used for treatment of non-alcoholic fatty liver disease. For this purpose administered are metronidasol 250 mg 4 times per day, alpha-normix 200 mg 2 tablets x 2 times per day during 7-10 days.After that, treatment is performed with further administration of bifiform in dose 2 capsules in the morning, probifor in dose 25-30 doses 3 times per day, linex in dose 2 capsules 3 times per day, hylak forte 40-60 drops 3 times per day, sporobacterin 2-4 ml. Duration of intake constitutes 3-4 weeks, also administered is dufalak in dose 5-10 ml per day. Drug therapy of lipid metabolism disorders is performed in dependence of biochemical parameters: in case if ultrasonic signs of steatosis are present and level of transaminases is normal, statins in combination with ezetimibe are administered. If transaminases increase to 3 normal values, essential phospholipids are applied during 3 months. If transaminases increase higher than 3 normal values, ursodeoxycholic acid in dose 15-20 mg/kg is applied; if ultrasonic signs of non-alcoholic steato hepatitis are present and transaminases increase to 3 normal values, statins are administered in dose 20 mg and ursodeoxycholic acid in dose 15-20 mg/kg for 3-6 months. If transaminases increase higher than 3 normal values, treatment is performed with statins in dose 20-40 mg/day and ursodeoxycholic acid in dose 15-20 mg/kg, ezetimibe in dose 10 mg 1 time per day.

Method of preventing vertical transmission of hepatitis b and c viruses in pregnant women with reactivation of viruses in third trimester / 2473341
Invention relates to field of medicine, namely to infectious diseases and obstetrics, and can be used for prevention of vertical transmission of hepatitis B and C viruses in pregnant women. For this purpose in pregnant women with term of pregnancy from 28 to 30 weeks with reactivation of chronic viral hepatitis B and C, level of viral load is determined and if its value is higher than 105 copies/ml, preparation Kipferon is introduced in dose 2 suppositories 2 times per day rectally with 12 hour interval during 14 days, and starting from 36 weeks of pregnancy repeated course is carried out in accordance with the same scheme.

Method of treating non-alcoholic steatohepatitis with application of dalargin magnetophoresis / 2473325
Invention relates to medicine, gastroenterology. Method includes dietotherapy in accordance with diet No 5, exercise therapy. Additionally intake of low-mineralised carbonaceous chloride-hydrocarbonate-sulfate-sodium-calcium mineral water "Essentuki-Novaya" is realised. Water is taken in in dose 3.5 ml per 1 kg of patient's body weight, 3 times per day, 30-40 minutes before meal. Carbonaceous-hydrogen sulfide mineral baths with content of hydrogen sulfide 15-20 mg/l are carried out every second day. Baths are taken with water temperature 36-37°C. Course includes 8-10 procedures. Dalargin magnetophoresis on liver projection is performed daily. Pulsing travelling magnetic field from apparatus AMO-ATOS is used. Magnetophoresis is carried out with induction 45 mT, with modulation frequency 10 Hz for 15 minutes, course includes 10 procedures.

Agent normalising liver mitochondria / 2470655
Invention refers to medicine, more specifically pharmacology. Grape seed extract is presented as an agent normalising liver mitochondria.

Agent possessing antiarrhythmic and hepatoprotective properties / 2469720
Invention refers to the use of 9-(2-diethylaminomethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole dihydrobromide of formula I: as an agent possessing antiarrhythmic and hepatoprotective properties. The invention also refers to the use of 9-(2-diethylaminomethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole dihydrobromide for preparing pharmaceutical compositions.

Use of polydatine for treating hepatic diseases and polydatine pharmaceutical composition / 2468803
There are presented the use of polydatine for treating toxic (including drug-induced) and alcoholic hepatic diseases, as well as based oral compositions. What is shown is reduction of a degree of hepatocyte adipose degeneration in sub-acute alcoholisation, reduction of glycemia and lactate-acidosis. Polydactine promoted reduction of synthesis and accumulation of glycosaminoglycans.

Method of preventing chronic toxic hepatopathy / 2468446
In order to prevent chronic toxic hepatopathy melaxen is introduced to animals in experiment one time per day in dose 10 mg/ml through probe into stomach. Simultaneously intragastric introduction of cobalt chloride solution in dose 2 mg/kg, in terms of metal, is performed daily, to create cobalt intoxication in organism.

Method for preparing agent showing cholagogue action / 2465000
Invention refers to pharmaceutical industry, specifically to an agent showing cholagogue action. A method for preparing the agent showing cholagogue action consisting in the fact that ground sandy everlasting blossom, nosebleed herb and peppermint leaves are mixed with coriander fruit, extracted in 40% ethanol by multistage counterflow extraction, settled, filtered, condensed under certain conditions.